Parmax Pharma Reports Negative Financial Results for Q4 2023, MarketsMOJO Issues 'Strong Sell' Call
Parmax Pharma, a microcap pharmaceutical company, has reported a negative performance in the quarter ending December 2023. The company's Profit Before Tax, Operating Profit, Profit After Tax, and Net Sales have all decreased, indicating a negative trend in the near term. MarketsMojo has given a 'Strong Sell' call for the company's stock.
Parmax Pharma, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending December 2023. The company has seen a negative performance in this quarter, with a score of -18, a significant decrease from 0 in the previous three months.
According to the financial report, the company's Profit Before Tax less Other Income (PBT) for the quarter has fallen to -201.73% Year on Year (YoY), indicating a very negative trend in the near term. The Operating Profit (PBDIT) for the quarter is also at its lowest, with a decrease in each of the last five quarters, showing a negative trend in the near term.
The company's Profit After Tax (PAT) for the quarter is also at its lowest, with a decrease in each of the last five quarters, indicating a very negative trend in the near term. The Net Sales for the half-yearly period have also shown a decline of -27.81% YoY, with a negative trend in the near term.
Furthermore, the company's Earnings per Share (EPS) for the quarter is at its lowest, with a decrease in the last five quarters. This indicates a declining profitability and lower earnings for shareholders.
Based on these financial results, MarketsMOJO has given a 'Strong Sell' call for Parmax Pharma's stock. The company's performance in the quarter ending December 2023 has not been favorable, and investors should be cautious while making any investment decisions.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
